modified Shenling Baizhu San

Phase 2Small molecule

CChinese University of Hong Kong

modified Shenling Baizhu San is one of 2 small molecule programs targeting Pneumoconiosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoconiosisNot yet recruiting

PneumoconiosisPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Pneumoconiosis

#DrugCompanyPhaseTrials

Esbriet

LLegacy Health System

Phase 3

1 2

modified Shenling Baizhu San

CChinese University of Hong Kong

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Pneumoconiosis

NCT07178184

Q3 2027

PreclinicalRecruiting

Atopic Dermatitis

NCT04419584

Phase 2Recruiting

Insomnia Chronic

NCT06511011

Clinical

Trials by Indication[1]

Atopic Dermatitis2 trials

A Randomized Placebo-Controlled Clinical Trial of an Innovative Herbal Formula for Atopic Dermatitis in Children: Evaluations of Modified Qing-Ying Decoction on Efficacy and Gut Microbiome

Recruiting·CChinese University of Hong Kong·Preclinical·NCT04419584·64 enrolled

A Randomized Placebo-Controlled Pilot Study of an Herbal Formula Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children

Completed·CChinese University of Hong Kong·Preclinical·NCT05613062·20 enrolled

Menopausal Syndrome1 trial

RCT on the Treatment of Menopausal Syndrome With Chinese Medicine

Unknown status·—·Phase 2·NCT06074809·78 enrolled

Pneumoconiosis1 trial

Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients

Not yet recruiting·—·Phase 2·NCT07178184·80 enrolled

Insomnia Chronic1 trial

Efficacy and Safety of Modified Suan ZaoRen Tang-TianWang BuXin Dan in the Treatment of Chronic Insomnia: A Randomized, Double-blinded, Placebo-controlled Trial

Recruiting·CChinese University of Hong Kong·Phase 2·NCT06511011·76 enrolled

Macula Edema1 trial

Efficacy and Safety of an Innovative Chinese Herbal Formula for the Treatment of Macular Edema: A Double-blind, Randomized, Placebo-Controlled Trial

Terminated·CChinese University of Hong Kong·Phase 2·NCT05122702·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for modified Shenling Baizhu San. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — modified Shenling Baizhu San compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for modified Shenling Baizhu San. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chinese University of Hong Kong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChinese University of Hong Kong

modified Shenling Baizhu San

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Atopic Dermatitis2 trials

Menopausal Syndrome1 trial

Pneumoconiosis1 trial

Insomnia Chronic1 trial

Macula Edema1 trial

References

Drug Info

Quick Facts

Related News